Recursion Pharmaceuticals announced results today for one its AI-discovered treatments. I was pleased to see the large, sustained reduction in polyps attributable to its treatment for Familial Adenomatous Polyposis. Recursions’ oral medication will be viewed by the traditional scientific and regulatory community as “promising”.
On the other hand, I was disappointed not to see/hear any reference to the savings of the cost to society from this treatment and a vague reference to working with the FDA in 1H2026. Quite frankly, the urgency seemed to be lacking.
